If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
341
results.
Updated on
15/11/2026 [08:23:00]
Results 75 to 100 of 341
Absstract of: CN114174813A
A method for assessing a biological condition associated with metal metabolism in a subject, the method comprising sampling a location along a biological sample of the subject to obtain a number of ion samples. Each ion sample corresponds to a location on the biological sample, and each location represents an amount of growth of the biological sample. The obtained ions are analyzed with a mass spectrometer, thereby obtaining a plurality of traces. Each such trace represents a concentration over time of a corresponding elemental isotope of a plurality of elemental isotopes. A set of features is derived from the trace. Each feature is determined by a change in a single isotope or combination of isotopes in the plurality of traces. The set of features is input into a trained classifier to obtain a probability that the subject has the biological condition associated with metal metabolism.
Absstract of: WO2025210040A1
The present invention provides a cell model to study Tau protein related diseases.
Absstract of: AU2015269198A1
This application describes a compound represented by Formula (I): (I)
Absstract of: CN122978230A
本发明公开了一种靶向Aβ1‑42寡聚体的阻断肽、阻断肽衍生物及其应用。本发明利用生物信息学手段，筛选出一条靶向Aβ1‑42的多肽。本发明筛选出的多肽能有效识别、结合Aβ1‑42寡聚体并改变其构象。将该多肽与Aβ1‑42同时处理SH‑SY5Y或MIN6细胞，可抑制由Aβ1‑42处理导致的细胞活力降低及乳酸脱氢酶释放增强，并抑制Aβ1‑42诱导的细胞内Ca2+浓度升高。这些结果表明本发明筛选出的多肽能够有效阻断Aβ1‑42寡聚体的功能，在阿尔茨海默病等Aβ沉积引起的神经系统疾病的临床治疗上具有广阔的应用前景。
Absstract of: WO2025068363A1
The present invention relates to a splice variant of an ICA1 protein that acts as a biomarker for a TDP-43 pathology. In particular, the present invention relates to methods for identifying a splice variant of ICA1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and/or reduced TDP-43 function in a subject.
Absstract of: CN122983386A
本申请涉及一种p‑tau 217的光激化学发光检测试剂、试剂盒及其应用。该检测试剂包括：包被于发光微球的特异性识别p‑tau 217的第一抗体和标记有特异性结合配对成员之一的特异性识别p‑tau 217的第二抗体；其中，第一抗体和/或第二抗体通过异肽键将其非特异性结合区域定向与目标物质偶联。本申请技术方案，能够提高光激化学发光检测过程中检测试剂包含的能够特异性识别p‑tau 217的有效抗体量，从而提高检测信号值，使得p‑tau 217的检测灵敏度达到飞克级，满足血浆中p‑tau 217的检测需求。
Absstract of: CN122983395A
0001 本发明涉及一种基于抗体定向固定工艺的p‑tau217磁微粒化学发光检测试剂盒，属于生物医学检测技术领域，由试剂A、试剂B和试剂C三部分组成，所述试剂A为内含有重组蛋白A包被的磁微粒工作液；所述试剂B含有重组蛋白A和吖啶酯共同标记的抗p‑tau217检测抗体工作液；所述试剂C为抗p‑tau217捕获抗体工作液，本发明利用重组蛋白A对抗体Fc片段的高特异性亲和力，实现了抗p‑tau217捕获抗体在磁珠表面的定向固定，避免了传统随机固定方式导致的Fab活性位点遮蔽或构象改变，最大限度地保留了抗体的抗原结合能力，显著提高了对痕量p‑tau217的捕获效率。
Absstract of: CN122983375A
0001 本发明公开了一种组织样本中细胞死亡类型的区分染色方法及试剂盒，所述区分染色方法包括染色步骤；所述染色步骤包括按照抗原顺序，使用对应的一抗依次对待测的肺组织样本进行孵育，使用染色剂对孵育后的样本进行染色，得到染色后的样本：抗原顺序依次为：Caspase‑1、LDH‑B、CD68、Gasdermin D、Caspase‑3、Cleaved PARP。本发明主要解决了多重免疫荧光技术进行脓毒症免疫微环境分析的需求，对单张切片进行多重免疫荧光实验，同时呈现六个抗原靶标的表达情况，可显著提高单张组织样本的利用率，尤其是珍贵样本。
Absstract of: CN122983387A
0001 本申请涉及一种p‑tau 217的光激化学发光检测方法及其应用。该方法通过将待测样本与包含第一抗体、第二抗体的反应体系相互接触，得到免疫反应产物，并检测所述免疫反应产物的光信号强度；其中，所述第一抗体和/或第二抗体通过异肽键将其非特异性结合区域定向与目标物质偶联。本申请技术方案，能够提高光激化学发光检测过程中检测试剂包含的能够特异性识别p‑tau 217的有效抗体量，从而提高检测信号值，使得p‑tau 217的检测灵敏度达到飞克级，满足血液样本中p‑tau 217的检测需求。
Absstract of: KR20260154496A
0001a 본 발명은 로다민 B 기반의 화합물 또는 이의 입체 이성질체에 대한 것이다. 상기 양친매성 화합물은 구리 이온과 결합하는 특징 및 금속 이온과 결합 시 형광을 방출하는 특징을 나타내므로, 이를 포함하는 조성물은 구리 이온, 특히 세포안에 존재하는 구리 1가 이온을 검출하는데 유용하게 사용될 수 있다.
Absstract of: WO2024243362A1
In some aspects, the present disclosure provides a computer-implemented method of predicting efficacies of drugs in a diversity drug set. In general, a computing system receives test results for drugs in a principal drug set for samples of a subject. The computing system trains at least one machine learning model to generate functional predicted results of drugs in the diversity drug set based on the test results for drugs in the principal drug set, and predicts functional predicted results of drugs in the diversity drug set by providing features of the drugs in the diversity drug set as input to the at least one machine learning model.
Absstract of: CN121253817A
The invention discloses a kit and a method for detecting ApoE4 protein in blood and application of the kit and the method. The kit comprises a magnetic bead coated with an ApoE capture antibody, an ApoE4 detection antibody labeled by a chemiluminescence marker, and a pre-excitation liquid and an excitation liquid required by chemiluminescence detection.
Absstract of: CN106170563A
Disclosed herein are methods and compositions for treating, ameliorating, and/or preventing Alzheimers disease in ApoE4-postitive patients using particular compounds and compositions thereof.
Absstract of: CN122958597A
本发明涉及基因工程和细胞工程领域，尤其涉及抗人源蛋白激酶CPKC的单克隆抗体 4G7G5和核酸和细胞株和载体及其用途和制备方法。所述单克隆抗体与PKC蛋白的解离常数（KD）为2.26×10⁻9 M，结合速率常数（Ka）为1.50×105 1/Ms，解离速率常数（Kd）为3.39×10⁻4 1/s；所述单克隆抗体的纯度经SDS‑PAGE电泳分析≥90%；所述单克隆抗体经间接ELISA法测定针对人源PKC/PKCδ蛋白的效价≥1093.5K；所述单克隆抗体以含有PBS pH7.4 + 1%蔗糖 + 0.05‰防腐剂的缓冲液作为保存液，浓度为0.95 mg/mL，体积为2.0 mL。
Absstract of: CN122958607A
0001 本发明涉及生物医学技术领域，具体涉及一种融合蛋白、复合物、试剂组合、用于检测Aβ1‑42含量的产品及应用。本发明提供的融合蛋白包括检测抗体、亲和素标签和青色荧光蛋白；所述检测抗体可特异性结合待测抗原Aβ1‑42，所述检测抗体包括Fc区；所述亲和素标签和青色荧光蛋白依次连接于所述Fc区的羧基端。本发明提供的融合蛋白成本低廉、批间差异稳定可控、操作简单，检测血清中Aβ1‑42灵敏度高、检测结果准确、反应时间短。
Absstract of: JP2026171710A
【課題】試料中に含まれる神経系細胞に由来する細胞外小胞を特異的に回収する方法を提供する。【解決手段】試料中に含まれる神経系細胞に由来する細胞外小胞に存在するＡＰＬＰ１を標的として抗ＡＰＬＰ１抗体を用いて免疫沈降を行った後、ペプチドを用いて解離することによって、上記の課題を解決する。【選択図】図１
Absstract of: CN122971564A
本公开属于生物医药领域，具体涉及靶向IL‑6R和IL‑1R1双功能融合蛋白及其应用。本公开的双功能融合蛋白对IL‑6R和/或IL‑1R1具有较好的亲和力和/或生物学活性，可用于检测IL‑6R和/或IL‑1R1、诊断或防治与IL‑6R和/或IL‑1R1相关的疾病或病症。
Absstract of: CN122958598A
0001 本发明涉及免疫学检测与抗体工程技术领域，具体涉及一种靶向人SIRT1蛋白的抗体组合物及其应用。抗体组合物包含S1‑M F4、S1‑P E7和S1‑P H2中的至少一种单克隆抗体，S1‑M F4、S1‑P E7和S1‑P H2均包含重链可变区和轻链可变区，该抗体组合物可用于制备人SIRT1蛋白的检测产品。本发明提供的单克隆抗体对SIRT1蛋白表现出高亲和力，且不与人SIRT3、SIRT6蛋白发生交叉反应，不易受干扰，并可相互配对形成捕获抗体和检测抗体的抗体对实现SIRT1蛋白的检测，特异性强，检测灵敏度高。本发明的抗体有希望开发成为针对SIRT1蛋白检测的专门产品，具有较好的应用前景。
Absstract of: CN122958534A
本发明属于医学诊断技术领域。更具体地，涉及一种HIV相关神经认知障碍的诊断标志物及其应用。本发明首次从HIV相关神经认知障碍患者脑脊液中鉴定出淀粉样多肽HAP‑4，证实其是引发认知功能衰退的核心病理分子，可作为HIV相关神经认知障碍的标志物。本发明基于淀粉样多肽HAP‑4成功制备高亲和力单克隆抗体，成功构建双抗夹心定量检测系统。该系统灵敏度高、特异性强，可精准捕获临床样本中致病聚集态淀粉样多肽HAP‑4。临床验证表明，该系统能有效区分HIV相关神经认知障碍患者、无症状HIV感染者及健康人群。本发明为HIV相关神经认知障碍早期筛查及诊断试剂盒开发提供了可靠靶点，具有较高的临床转化潜力与推广价值。
Absstract of: CN122962077A
本发明公开了一种信号自补偿抗污染的同型半胱氨酸比率电化学适配体传感器及其制备方法。该传感器包括玻碳电极、修饰于电极表面的AuNPs/MXene复合膜、负载于复合膜中的亚甲基蓝内标分子、通过Au‑S键自组装的同型半胱氨酸特异性适配体以及牛血清白蛋白封闭层。本发明首次利用BSA封闭与比率信号的协同抗污染机制：BSA封闭导致Hcy响应电流和内标电流同步衰减，但两者比值保持基本恒定，实现了“MXene超亲水表面+BSA物理封闭”与“比率信号自补偿”的多重抗污染。该传感器对结构类似物的干扰信号低于5%，15天内比值变化率仅为2.04%，在极端污染环境（电极经BSA浸泡预处理30分钟）中加标回收率仍高达94.2%。采用差示脉冲伏安法检测，Hcy的氧化峰电流与亚甲基蓝的氧化峰电流之比与Hcy浓度在3.25 nM~150 μM范围内呈良好线性关系，检测限低至1.08 nM。本发明具有选择性高、长期稳定性好、抗污染能力强、制备工艺简单等优点，可用于血清样本中同型半胱氨酸的准确检测。
Absstract of: CN122958584A
本申请公开了一种用于磷酸化Tau蛋白pTau231检测的抗体、免疫检测方法及应用。本申请抗体包括T231‑1A4抗体；T231‑1A4的轻链CDR1、CDR2和CDR3依序为SEQ ID NO.1至3所示序列，重链CDR1、CDR2和CDR3依序为SEQ ID NO.4至6所示序列。基于本申请抗体对磷酸化Tau蛋白pTau231进行免疫检测，操作简单、灵敏度高、特异性强，可实现磷酸化Tau蛋白pTau231快速检测，对评估Tau蛋白磷酸化水平和Tau蛋白pTau231磷酸化相关检测具有重要意义。
Absstract of: CN122959410A
0001 本发明公开了一种中枢神经系统线粒体功能稳态的评估方法，步骤：获取外周血样本，检测Mcu和DPP4表达水平，据此评估线粒体功能稳态，并涉及该方法的用途。本方案以睡眠剥夺认知损伤为切入点，但线粒体障碍普遍存在于阿尔茨海默病、帕金森病、脑卒中后认知障碍及衰老相关认知衰退等疾病，适用广。检测采用ELISA和线粒体染色等成熟常规技术，易标准化、成本低，市场前景好。核心方法可推广至任何影响Mcu表达或功能的药物或干预手段，保护范围宽。此外，将基础发现与临床需求结合，尤其与源自农业废弃物的尿石素A联用，兼具“变废为宝”和大健康产业转化潜力。
Absstract of: US20260328784A1
0000 Alpha-Synuclein mutants and uses thereof are disclosed herein. The mutants of the present invention are non-self-aggregating forms of Alpha-Synuclein which make them a suitable candidate for use as substrates in aggregation assay for evaluating the presence of misfolded α-Syn protein. Also disclosed are kits and method for detection of synucleinopathies in individuals, using the mutants of the present invention.
Absstract of: US20260328785A1
0000 The present invention relates to the field of virology. More specifically, the present invention provides compositions and methods for assessing the severity of and treating severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) or COVID-19. In particular embodiments, a method for treating COVID-19 in a patient comprises the step of administering to the patient an isolated, recombinant antibody or antigen-binding fragment thereof that binds human Resistin.
Nº publicación: US20260325565A1 22/10/2026
Applicant:
THE BROAD INST INC [US]
MASSACHUSETTS INST OF TECHNOLOGY [US]
The Broad Institute, Inc.
Massachusetts Institute of Technology
Absstract of: US20260325565A1
Mammals rely on adaptive immunity to protect against infections and tumors, with the thymus playing a crucial role by producing T cells that target infected or cancerous cells. The thymus, however, undergoes functional decline with age, significantly impairing the immune system in the elderly. To investigate reversing this decline, compositions and methods for activation and differentiation of T cell progenitors in extrathymic tissues are disclosed that stimulate production of differentiated T cells. For example, LNP-mediated delivery of mRNAs encoding DLL-1, IL-7, and FLT3L to the liver is shown to create a temporary site for T cell maturation that enhances T cell-mediated immunity in aged mice without causing autoimmunity. This approach facilitates ectopic T cell development from hematopoietic precursors and activates dendritic cells, providing evidence that engineering adaptive immunity in vivo can effectively mitigate immune aging.
BOPI
Electronic site
